UTRECHT, The Netherlands, November 2 InteRNA TechnologiesB.V. and the Dana-Farber Cancer Institute (Boston, USA) have entered into aresearch agreement to develop microRNA (miRNA)-based therapeutics for cancer.
Under the research collaboration with Associate Professor William C.Hahn, MD, PhD (Department of Medical Oncology), InteRNA's uniquelentiviral-based miRNA overexpression library will be applied inmulti-parametric, high-throughput functional screening assays to identify thebiological role of individual miRNAs and novel therapeutic targets in diversecancer pathways.
"We are very excited about this collaboration with Dr. Hahn, a renownedcancer investigator, and the Dana-Farber, as it allows for functional screensin diverse cell based assays embedded in a lab with extensive knowledge ofcancer", said Roel Schaapveld, Chief Executive Officer of InteRNATechnologies.
"These functional screens hold great promise to help us better understandthe roles of miRNAs in cancer and to identify potential treatment targets,"said Dr. Hahn of Dana-Farber Cancer Institute.
About InteRNA Technologies B.V.
InteRNA Technologies B.V. actively explores and exploits opportunities totranslate its unique collection of miRNAs and miRNA discovery and validationtechnologies into successful diagnostic, prognostic and therapeuticapplications. The company's primary focus is to unravel the role of itsproprietary miRNAs in cancer.
InteRNA Technologies was incorporated in 2006 by Aglaia Oncology Fund andhas established close relationships with the research groups of its foundersEdwin Cuppen, PhD, and Eugene Berezikov, PhD, of the Hubrecht Institute(Utrecht, the Netherlands), leading scientific groups in the field of miRNAresearch.
See for more information http://www.interna-technologies.com.
SOURCE InteRNA Technologies B.V.